3.722

3.14% 0.102

Biodexa Pharmaceuticals Plc Adr (BDRX)

Overview News Price History Why BDRX Down? Discussions Forecast Stock Split

Biodexa Pharmaceuticals Plc Adr stock is traded at $3.722, with a volume of 22,559. It is up +3.14% in the last 24 hours and down -34.49% over the past month. Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

Previous Close:

$3.62

Open:

$3.7

24h Volume:

22,559

Relative Volume:

0.14

Market Cap:

$2.10M

Revenue:

$644.60K

Net Income/Loss:

$-9.87M

P/E Ratio:

-0.00444

EPS:

-837.9618

Net Cash Flow:

$-9.02M

1W Performance:

-27.50%

1M Performance:

-34.49%

6M Performance:

-87.45%

1Y Performance:

-94.23%

1-Day Range:

$3.60

$3.80

1-Week Range:

$3.51

$5.45

52-Week Range:

$3.51

$220.25

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile

Name

Biodexa Pharmaceuticals Plc Adr

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

Address

Employee

Twitter

Next Earnings Date

2024-06-13

Latest SEC Filings

BDRX's Discussions on Twitter

Compare BDRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDRX	3.722	2.10M	644.60K	-9.87M	-9.02M	-837.96
VRTX	467.64	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	761.02	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	564.78	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	230.25	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.63	24.08B	3.30B	-501.07M	1.03B	11.54

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Latest News

Nov 12, 2024

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Oct 29, 2024

Oct 17, 2024

Biodexa reports promising glioblastoma trial results - Investing.com

Oct 17, 2024

Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study - TipRanks

Oct 17, 2024

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan

Oct 17, 2024

Oct 16, 2024

Stock Surge: Biodexa Pharmaceuticals Plc ADR (BDRX) Closes at 5.01, Marking a -4.21 Increase/Decrease - The Dwinnex

Oct 16, 2024

Oct 15, 2024

Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks

Oct 15, 2024

Biodexa secures Nasdaq listing extension - Investing.com

Oct 15, 2024

Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks

Oct 15, 2024

Biodexa secures Nasdaq listing extension By Investing.com - Investing.com UK

Oct 15, 2024

Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan

Oct 15, 2024

Oct 05, 2024

Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - TipRanks

Oct 05, 2024

Oct 04, 2024

Biodexa reports survival rates in glioblastoma study - Investing.com India

Oct 04, 2024

Biodexa reports updated Phase 1 data from glioblastoma study (NASDAQ:BDRX) - Seeking Alpha

Oct 04, 2024

Biodexa’s MTX110 Shows Promise in Brain Cancer Study - TipRanks

Oct 04, 2024

Biodexa reports survival rates in glioblastoma study By Investing.com - Investing.com UK

Oct 04, 2024

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - StockTitan

Oct 04, 2024

Oct 03, 2024

Ratio Analysis: Unpacking Biodexa Pharmaceuticals Plc ADR (BDRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 03, 2024

Oct 02, 2024